Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma

Affiliations

¹ Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
² Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Editorial

Ansam Sinjab et al. J Thorac Dis. 2019 Mar.

. 2019 Mar;11(Suppl 3):S216-S219.

doi: 10.21037/jtd.2019.02.29.

¹ Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
² Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. Aisner DL, et al. Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7. Clin Cancer Res. 2018. PMID: 29217530 Free PMC article.

1. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-77. 10.1097/JTO.0000000000000516 - DOI - PMC - PubMed
1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006. 10.1001/jama.2014.3741 - DOI - PMC - PubMed
1. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 2015;121:448-56. 10.1002/cncr.29042 - DOI - PMC - PubMed
1. Aisner DL, Sholl LM, Berry LD, et al. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 2018;24:1038-47. 10.1158/1078-0432.CCR-17-2289 - DOI - PMC - PubMed
1. Kim IA, Lee JS, Kim HJ, et al. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. BMC Cancer 2018;18:768. 10.1186/s12885-018-4691-0 - DOI - PMC - PubMed